David Weingeist

Company: Johnson & Johnson Services, Inc

Job title: Scientific Director & Oncology Diagnostics Leader

Seminars:

H&E-Based Biomarker Profiling In Precision Medicine: Opportunities & Challenges 2:40 pm

Exploring opportunities, challenges and practical takeaways of H&E base biomarker Profiling across a variety of different applications (research, drug development, the clinic)Read more

day: Day Three Track A

Panel Discussion: Considering Digital Pathology & AI/ML from a Drug Development Pipeline Perspective 1:25 pm

What are the greatest barriers to routine digital pathology clinical use? What approaches can we take to overcome them? Translational studies – leveraging digital pathology to describe populations Leveraging digital pathology to define clinical endpointsRead more

day: Day Three Track A

Advancing Precision Medicine in Early Bladder Cancer with Urine Assay Technology 12:10 pm

Urine-based genomic analysis has the potential to become a standard liquid biopsy approach in early bladder cancer Urine enables convenient and reliable, non-invasive patient screening, addressing certain challenges of tissue and plasma-based testing The highly sensitive method detects a broad spectrum of genomic alterations, enhancing its clinical utility beyond treatment selectionRead more

day: Day One